PT-141 (Bremelanotide): A Research Overview

Introduction

PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from the research lineage of alpha-melanocyte-stimulating hormone (alpha-MSH). The compound was developed by Palatin Technologies and received regulatory approval in the United States under the brand name Vyleesi in 2019 — the first FDA-approved melanocortin receptor agonist for any therapeutic indication. Published research has characterized its receptor selectivity, molecular pharmacology, and clinical profile across a series of peer-reviewed studies spanning more than two decades. This article provides an educational reference overview of bremelanotide's chemical identity, pharmacological classification, and regulatory history.

Background

The melanocortin system comprises a family of endogenous peptide hormones — principally adrenocorticotropin (ACTH) and the melanocyte-stimulating hormones (MSH) — along with five G protein-coupled receptors designated melanocortin receptors 1 through 5 (MC1R–MC5R). These receptors mediate a diverse range of physiological processes including pigmentation, energy homeostasis, inflammation, and neurological function [1].

Research on melanocortin receptor pharmacology accelerated in the 1980s and 1990s following the identification of receptor subtypes and the development of selective synthetic agonists. At the University of Arizona, Victor Hruby and colleagues synthesized cyclic peptide analogs of alpha-MSH aimed at identifying the structural determinants of receptor selectivity. Two analogs — melanotan I (a linear peptide) and melanotan II (a cyclic, truncated peptide) — were characterized and entered early clinical investigation, with melanotan II subsequently identified as the structural progenitor of bremelanotide [2].

Chemistry and Structure

Bremelanotide is a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The ring closure is formed by a lactam bond between the aspartate and lysine side chains. The molecular formula is C₄₉H₆₄N₁₄O₁₀ and the molecular weight is approximately 1,025 daltons [3].

The compound is structurally derived from melanotan II by the substitution of a single amino acid residue, converting the C-terminal amide of melanotan II to a free hydroxyl group. This modification alters the compound's receptor interaction profile and pharmacokinetic behavior relative to its structural progenitor. The incorporation of D-phenylalanine at a key position contributes to the compound's resistance to enzymatic cleavage and prolongs its biological activity relative to the natural alpha-MSH tridecapeptide ligand.

Following subcutaneous administration, bremelanotide reaches maximum plasma concentration within approximately one hour and has a mean terminal half-life of approximately 2.7 hours [3]. Primary metabolism proceeds via hydrolysis of the peptide bonds; renal excretion accounts for the majority of elimination.

Pharmacological Classification

Bremelanotide is classified as a melanocortin receptor agonist with selective activity at the MC3R and MC4R subtypes. Both receptors are expressed primarily in the central nervous system, with MC4R distributed throughout the hypothalamus, limbic system, and brainstem [4]. Bremelanotide's central receptor profile distinguishes it mechanistically from PDE5 inhibitors, which act through a peripheral vascular mechanism.

Hadley and Dorr (2006) reviewed the historical development of melanocortin peptide therapeutics and noted that the melanocortin system's central neurological distribution provided a mechanistic rationale for exploring these compounds in contexts involving appetite regulation, neuroendocrine function, and centrally mediated responses [2]. Bremelanotide was distinguished from earlier analogs by its pharmacokinetic profile and receptor selectivity.

The compound's central mechanism of action — engaging MC3R and MC4R within hypothalamic and limbic structures — represents a pharmacologically distinct class from the peripheral vascular compounds that preceded it in clinical development [2, 3].

Regulatory Status

Bremelanotide (Vyleesi) received approval from the United States Food and Drug Administration (FDA) on June 21, 2019, under New Drug Application (NDA) 210557. The approved indication is the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [3]. The approval was based on data from the RECONNECT phase 3 clinical program, which enrolled 1,267 premenopausal women across two parallel randomized controlled trials and demonstrated statistically significant improvements on both co-primary endpoints [5].

The approval marked the first FDA authorization of any compound acting through melanocortin receptor agonism, reflecting the maturation of three decades of basic receptor pharmacology research into a clinical regulatory outcome. Research-grade PT-141 from SpartaLabs is verified by independent third-party HPLC and mass spectrometric analysis.

The prescribing information includes precautionary guidance for patients with controlled hypertension, consistent with the known cardiovascular pharmacology of melanocortin receptor agonism [3]. Bremelanotide is not FDA-approved for use in men, postmenopausal women, or any other indication beyond the approved label.

Discovery History

The chemical lineage of bremelanotide begins with the characterization of alpha-MSH as a pituitary-derived tridecapeptide and the subsequent delineation of melanocortin receptor subtypes. Research at the University of Arizona during the 1980s and 1990s produced cyclic peptide analogs of alpha-MSH with enhanced receptor potency and resistance to enzymatic degradation — a structural platform that ultimately yielded the bremelanotide clinical candidate [2].

Palatin Technologies licensed and further developed bremelanotide from the melanotan II structural scaffold. Early clinical programs explored multiple administration routes; subcutaneous delivery was advanced following comparative pharmacokinetic characterization that demonstrated more predictable bioavailability than the intranasal route studied in earlier programs [6]. Clinical development proceeded through phase 1 and phase 2 dose-finding studies before advancing to the pivotal phase 3 RECONNECT trials.

The compound's regulatory approval in 2019 represented the culmination of approximately three decades of research tracing from foundational alpha-MSH analog chemistry to the first approved melanocortin receptor agonist in any therapeutic category.

References

1. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Pharmacol Rev. 2022. PMC: PMC9599618. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/

2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534. DOI: 10.1016/j.peptides.2005.01.029

3. US Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. Approved June 21, 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

4. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131-141. PMID: 9019399. DOI: 10.1016/s0092-8674(00)81865-6

5. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500

6. Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health Issues. 2017;27(3):365-372. PMC: PMC5384512. DOI: 10.1016/j.whi.2017.01.002